scholarly journals Hoigne Syndrome Caused by Intralesional Meglumine Antimoniate

2017 ◽  
Vol 5 (4) ◽  
pp. 483-485 ◽  
Author(s):  
Claudio Guarneri ◽  
Georgi Tchernev ◽  
Uwe Wollina ◽  
Torello Lotti
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Medical Literature ◽  
Meglumine Antimoniate ◽  
First Case ◽  
Intralesional Administration

Hoigne syndrome (HS) is the term coined to describe an acute, non-allergic, psychiatrically based reaction occurring with a wide list of medications, mainly antibiotics. Since its first description by Hoigne and Schoch in 1959, few cases have been reported in medical literature and, although antimicrobials are commonly used, very rarely in dermatology. The authors describe the first case occurred after intralesional administration of meglumine antimoniate and briefly discuss the pathogenetic hypotheses on this atypical adverse drug reaction.

Case of relapsing sulfasalazine-induced hypersensitivity syndrome upon re-exposure

2020 ◽  
Vol 13 (9) ◽  
pp. e235803 ◽  
Author(s):  
Jason Winward ◽  
Laurel Lyckholm ◽  
Samuel M Brown ◽  
Mohamad Mokadem
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Crohn’S Disease ◽  
Hypersensitivity Syndrome ◽  
Morbidity And Mortality ◽  
Significant Morbidity ◽  
Timely Initiation ◽  
Source Of Infection ◽  
First Case ◽  
Appropriate Treatment

Sulfasalazine-induced hypersensitivity syndrome (SIHS) is a serious systemic delayed adverse drug reaction that is associated with significant morbidity and mortality. Here, we report the first case, to our knowledge, of a patient with previously unidentified SIHS who developed a significantly more rapid and extreme recurrence on re-exposure to sulfasalazine. The patient is a 58-year-old woman with asymptomatic Crohn’s disease who, 10 days after initiating sulfasalazine, developed fevers, diffuse rash, pancytopenia, hypotension and hepatitis without a definitive source of infection. Sixteen days after her first hospitalisation, she was restarted on sulfasalazine and was readmitted within 10 hours with a similar but more serious presentation, requiring vasopressors. She did recover completely without any further recurrence to date, after definitively discontinuing sulfasalazine. This case demonstrates the importance of recognising SIHS early in patients to prevent re-exposure to sulfasalazine and to ensure timely initiation of appropriate treatment.

scholarly journals A rare case of Colistin induced maculopapular rash

2020 ◽  
Vol 14 (08) ◽  
pp. 929-930
Author(s):  
Mandalapu Laasya ◽  
Ann V Kuruvilla
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Rare Case ◽  
Maculopapular Rash ◽  
Antibiotic Use ◽  
Hospitalized Patients ◽  
First Case ◽  
Cutaneous Reactions ◽  
Polymyxin E

Approximately 2–3% of hospitalized patients are known to experience an adverse drug reaction (ADR). Dermatologic ADRs account for 10–30% of ADRs, and are commonly reported to be associated with antibiotic use. The classes of antibiotics most commonly reported to cause cutaneous reactions are the penicillins, cephalosporins, and fluoroquinolones. Polymyxin E is known to cause such reactions, but rarely. Here, we report a case of a colistin- induced maculopapular rash in an 84-year-old male. To the best of our knowledge, this is the first case of colistin-induced maculopapular rash to be reported in India.

scholarly journals Petechia of the Penis: Sexual Habits or Adverse Drug Reaction?

2018 ◽  
Vol 12 (3) ◽  
pp. 167-168
Author(s):  
Claudio Marasca ◽  
Milena Cappello ◽  
Cataldo Patruno ◽  
Dario Marasca ◽  
Lorenzo Squillace ◽  
...  
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Acetylsalicylic Acid ◽  
Oral Sex ◽  
Cutaneous Lesions ◽  
First Case

To the best of our knowledge, we report the first case of recurring small red macules (petechia), exclusively localized on the gland secondary to fellatio in an adult man, who is on therapy with acetylsalicylic acid. No previous studies have been ever conducted on the possible onset of penis petechia after oral sex. Petechia are nonspecific cutaneous lesions appearing as circumscribed sub-epithelial hemorrhages, or appearing as small dark red or purplish spots as a result of capillaries rupture.

scholarly journals Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case

Reumatismo ◽  
2019 ◽  
Vol 71 (2) ◽  
pp. 99-102 ◽  
Author(s):  
V. Shobha ◽  
A.M. Desai ◽  
T. Matthew
Keyword(s):  
Adverse Drug Reaction ◽  
Nervous System ◽  
Drug Reaction ◽  
Tumor Necrosis ◽  
Treatment Guidelines ◽  
Guillain Barre Syndrome ◽  
First Case ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Necrosis Factor

Anti-tumor necrosis factor drugs are used routinely according to treatment guidelines for several chronic rheumatologic problems. However, a rare and usually unpredictable adverse drug reaction namely peripheral nervous system demyelination is being increasingly recognized. Biosimilars are gaining momentum especially in countries like India. Hence, we report a case of Guillain-Barré syndrome secondary to an etanercept biosimilar, probably the first case reported so far.

Biperiden-Induced Delirium In A Five-Years Old Child

2019 ◽  
Vol 14 (1) ◽  
pp. 48-50 ◽  
Author(s):  
Duygu Kınay ◽  
Ahmet Zihni Soyata
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Adverse Effects ◽  
Antipsychotic Drugs ◽  
Separation Anxiety Disorder ◽  
Electrolyte Imbalance ◽  
Treatment Center ◽  
Anticholinergic Agent ◽  
Oppositional Defiant ◽  
First Case

Objective: Extrapyramidal adverse effects of antipsychotic drugs are more reported in children. Biperiden is an anticholinergic agent to treat the adverse effects of antipsychotic drugs. The drug has the potential to induce delirium at toxic doses. However, data are scarce about delirium associated with biperiden in children. Thus far, a case of delirium has been associated with biperiden in an adolescent patient. We report the first case of delirium associated with the use of biperiden in a preadolescent patient. Case Report: A boy aged five years and weighing 20 kilograms had been diagnosed as having oppositional defiant disorder and separation anxiety disorder in the previous treatment center. Ten milligrams fluoxetine and 0.25 milligrams risperidone had been initiated. On the third day of treatment, dystonia developed and he was administered with biperiden. An hour later, he was brought to our emergency clinic due to disorganized speech and behavior. His vital signs were stable. There were no findings in blood and urine tests. No electrolyte imbalance, liver, kidney, and thyroid dysfunction have been observed. His neurologic examination was unremarkable and no abnormal findings were shown on cranial magnetic resonance imaging. No other system findings or findings pointing out to infectious diseases have been observed. One milligram physostigmine was administered with intravenous infusion. However, symptoms did not resolve and he was diagnosed with delirium. Naranjo Adverse Drug Reaction Probability Scale score was seven, indicating a “Probable” Adverse Drug Reaction. Half milligram haloperidol was administered bid for three days and he was discharged with complete recovery. Conclusion: Clinicians must be aware of the risk of delirium when using non-toxic doses of biperiden in young children.

scholarly journals Suspected Agomelatine-induced restless legs syndrome: a case report

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Mustafa Abdul Karim ◽  
Nadeen Al-Baz ◽  
Sami Ouanes ◽  
Majid Alabdulla ◽  
Peter M. Haddad
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Case Report ◽  
Restless Legs Syndrome ◽  
Lower Limbs ◽  
Complete Relief ◽  
Restless Legs ◽  
First Case ◽  
Primary Disorder

Abstract Background Restless Legs Syndrome (RLS) is a sensorimotor disorder characterized by unpleasant and distressing sensations in the lower limbs that are more pronounced in the evening, commence or worsen at rest, and show partial or complete relief following movement. It can occur as a primary disorder, secondary to medical conditions or treatment with medications including but not limited to antidepressants or antipsychotics. Case presentation A 32-year old man with major depressive disorder showed partial response to Escitalopram 10 mg daily. Agomelatine 25 mg at night was added to Escitalopram to treat his residual depressive symptoms, namely insomnia and tiredness. Within two days he developed restlessness and unpleasant sensations in his legs which were worse at night. Symptom severity increased over the following days, prompting an urgent consultation a week later. The patient’s presentation met the criteria for RLS. Agomelatine was discontinued leaving the patient on Escitalopram alone. The patient’s symptoms improved within 24 h of stopping Agomelatine, with complete resolution four days later. There was no recurrence of RLS during follow-up. The patient scored 6 on Naranjo’s adverse drug reaction probability scale, indicating a probable adverse drug reaction caused by Agomelatine. Conclusions To the best of our knowledge, this is the first case report of suspected Agomelatine-induced RLS. Clinicians need to be aware of RLS to enable prompt diagnosis and management. We suggest adding Agomelatine to the list of agents that can potentially induce RLS.

Difficulties in the detection of the culprit drug for an adverse drug reaction in a complicated case

2008 ◽  
Vol 149 (19) ◽  
pp. 883-887 ◽  
Author(s):  
Henriette Kopcsányi ◽  
Julianna Feldmann ◽  
Zsófia Péch ◽  
Ágnes Jurcsik
Keyword(s):  
Adverse Drug Reaction ◽  
Drug Reaction ◽  
Complicated Case ◽  
Erythema Exsudativum Multiforme ◽  
Culprit Drug

Az adverz gyógyszerreakciók különféle klinikai megjelenési formái alapján a kiváltó gyógyszerre nehéz következtetni. A gyanúba vett gyógyszerek elhagyása után fellépő javulás vagy az empirikus tapasztalat, esetleg irodalmi adatok alapján lehet a felelős gyógyszert feltételezni. A gyógyszerérzékenység bizonyítása bonyolult, jól átgondolt orvosi tevékenység útján lehetséges, és azokban az esetekben szükséges, amikor a gyanús gyógyszer más vegyületcsoportba tartozó szerrel nem helyettesíthető, és a betegnek feltétlenül szükséges szednie. A jelen közlemény célja egy eset kapcsán körvonalazni azokat a lehetőségeket és veszélyeket, melyek a kivizsgálás során alkalmazhatók, illetve megjelenhetnek. A kivizsgálás során használt módszerek a gyanúba vett gyógyszerekkel – lamotrigin, risperidon, sertralin – zopiclonum, atorvastatin elvégzett epicutan teszt során egyedül a sertralin adott a multiform tünetekkel azonos pozitív reakciót. A pozitív bőrteszt területéről készült hisztológiai vizsgálat eredménye visszautalt az eredetileg észlelt klinikai formára (erythema exsudativum multiforme Stevens–Johnson-szindróma). A beteg bipoláris affektív zavara miatt a negatív bőrtesztet adó készítményekkel per os provokáció történt, ez azonban a beteg számára kockázatos, de az egyetlen megbízható és biztos módszer. Az elvégzett per os expozíció során a törzsön a lamotrigintől már tört adag bevételét követően három órán belül diffúz erythema, 12 órán belül az alkalmazott szteroid- és antihisztamin-kezelés ellenére scarlatiniform exanthema jelent meg. Az eset érdekessége, hogy a gyanúba vett gyógyszerek során epicutan teszttel egy gyógyszer érzékenysége igazolódott, azonban a másik gyanúba vett készítménnyel végzett pozitív per os expozíciós próba is váratlanul tünetet provokált (scarlatiniform, azonnali reakciót). Megállapítható, hogy csupán egy bizonyos módszer még a klinikai képpel való egyező eredmény alapján sem elegendő adverz gyógyszerreakció provokáló tényezőjének bizonyítására.

Sign in / Sign up

Export Citation Format

Share Document